Back In The Game: One Year After Rx Exit, P&G Signs On To Promote Silenor
This article was originally published in The Pink Sheet Daily
Executive Summary
Somaxon and P&G are preparing to launch the insomnia drug in September with a combined sales force of 215 reps.
You may also be interested in...
Somaxon's Silenor Gains An FDA Approval, But Can The Pharma Afford A Launch?
Somaxon hopes to launch its insomnia drug in the second half of 2010, but is still searching for a U.S. commercial partner.
Somaxon Sleep Aid Silenor Not Effective, FDA Says
In its second "complete response" letter for the chronic insomnia drug, FDA says Silenor fails to meet approval standards.
P&G Throws Weight Behind Consumer Growth After Shedding Pharma
Since many of its key consumer product lines are already mature U.S. brands, Procter & Gamble will have to drive growth by expanding into new markets and acquiring either hard-to-find licenses for OTC switch candidates or existing nonprescription brands.